Lithium cation

Generic Name: Lithium cation

Drug Type: Small Molecule

Chemical Formula: Li

CAS Number: 7439-93-2

Unique Ingredient Identifier: 8H8Z5UER66

Background: Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.

Indication: Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.

Associated Conditions: Bipolar Disorder (BD), Depression, Depression, Bipolar, Acute Manic episode

Clinical Trials

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

Phase 1

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium
Drug: Valproic acid

First Posted Date: 2007-11-27

Last Posted Date: 2012-05-01

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 98

Registration Number: NCT00563992

Locations: 🇺🇸
New York State Psychiatric Institute/Columbia University, New York, New York, United States

Continuation Ketamine in Major Depression

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Lithium
Drug: Ketamine

First Posted Date: 2007-10-25

Last Posted Date: 2014-05-23

Lead Sponsor: James Murrough

Target Recruit Count: 36

Registration Number: NCT00548964

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Suicide Prevention by Lithium - the Lithium Intervention Study

Not Applicable

Terminated

Conditions: Suicide
Depressive Disorders

Interventions: Drug: placebo
Drug: lithium

First Posted Date: 2007-08-23

Last Posted Date: 2007-08-23

Lead Sponsor: University Hospital Schleswig-Holstein

Target Recruit Count: 167

Registration Number: NCT00520026

Locations: 🇩🇪
Department of Psychiatry and Psychotherapy, Universitätsklinikum Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
🇩🇪
Department of Psychiatry and Psychotherapy, Rheinische Friedrich-Willhelms-Universität, Bonn, Germany
🇩🇪
Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

and more 2 locations

Pharmacotherapy of Treatment-Resistant Mania

Phase 3

Completed

Conditions: Mania

Interventions: Drug: Lithium
Drug: verapamil
Drug: verapamil plus lithium

First Posted Date: 2007-08-21

Last Posted Date: 2011-02-25

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 45

Registration Number: NCT00518947

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania

Phase 4

Completed

Conditions: Bipolar Depression

First Posted Date: 2007-04-05

Last Posted Date: 2011-09-28

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 60

Registration Number: NCT00457054

Locations: 🇺🇸
Indiana University Adult Psychiatry Clinic, Indianapolis, Indiana, United States

Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients

Phase 3

Completed

Conditions: Mania
Bipolar Disorder

First Posted Date: 2007-03-19

Last Posted Date: 2010-12-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 150

Registration Number: NCT00448578

Locations: 🇨🇳
Research Site, Wu han, China
🇨🇳
Research Sites, Beijing, China

Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide

Phase 3

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: lithium
Drug: paroxetine

First Posted Date: 2006-11-16

Last Posted Date: 2021-01-29

Lead Sponsor: Nova Scotia Health Authority

Target Recruit Count: 2

Registration Number: NCT00400088

Locations: 🇨🇦
Capital District Health Authority - Dept. of Psychiatry, Halifax, Nova Scotia, Canada

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

Phase 3

Completed

Conditions: Manic or Mixed Episode Associated With Bipolar I Disorder

Interventions: Drug: olanzapine
Drug: lithium
Drug: valproate
Drug: carbamazepine

First Posted Date: 2005-12-19

Last Posted Date: 2010-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 139

Registration Number: NCT00266630

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan